$13.3MVenture, 15 October 2025
Funds the Phase Ib proof of mechanism study of MTX325 in Parkinson's patients.
- Amount
- $13.3M
- Stage
- Venture
- Announced
- 15 October 2025
- Lead
- IP Group
- Other investors
- Rosetta Capital, Pfizer Venture Investments, SR One, Sofinnova Partners, Roche Venture Fund
- Use of funds
- Funds the Phase Ib proof of mechanism study of MTX325 in Parkinson's patients.
- Checked
- Announced by the company
- Sources
- MISSION Therapeutics raises EUR 11M (amount in EUR as listed by Tech.eu) missiontherapeutics.com
MISSION Therapeutics raises EUR 11M (amount in EUR as listed by Tech.eu) funding.tech.eu